Supernus Pharmaceuticals Files 8-K

Ticker: SUPN · Form: 8-K · Filed: 2025-06-16T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, filing

Related Tickers: SUPN

TL;DR

SUPN signed a material definitive agreement, filing an 8-K on June 16, 2025.

AI Summary

On June 13, 2025, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported other events and filed financial statements and exhibits. The filing was made on June 16, 2025.

Why It Matters

This 8-K filing indicates Supernus Pharmaceuticals has entered into a significant agreement, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which often carries significant implications for a company's future, but the specific nature of the agreement is not detailed.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Supernus Pharmaceuticals?

The filing does not disclose the specific details of the material definitive agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 13, 2025.

On what date was this 8-K filing submitted to the SEC?

The filing was submitted on June 16, 2025.

What is Supernus Pharmaceuticals' principal executive office address?

The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.

What is Supernus Pharmaceuticals' standard industrial classification?

The standard industrial classification is Pharmaceutical Preparations [2834].

From the Filing

0001104659-25-059687.txt : 20250616 0001104659-25-059687.hdr.sgml : 20250616 20250616083438 ACCESSION NUMBER: 0001104659-25-059687 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 32 CONFORMED PERIOD OF REPORT: 20250613 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250616 DATE AS OF CHANGE: 20250616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 251048613 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 tm2518064d1_8k.htm FORM 8-K false 0001356576 0001356576 2025-06-13 2025-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 13, 2025   Supernus Pharmaceuticals, Inc.  (Exact name of registrant as specified in its charter)   Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices)     (Zip Code)   Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act   Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   x Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 1.01 Entry into a Material Definitive Agreement.   On June 13, 2025, Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sage Therapeutics, Inc., a Delaware corporation (“Sage”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Sage and Saphire Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#

View on Read The Filing